BlossomHill Therapeutics, Inc. (BLSM) SEC Filings

BlossomHill Therapeutics, Inc. (BLSM) reported second quarter 2026 results, highlighting higher operating spending as it advances its oncology pipeline and prepares for later-stage trials. Research and development expenses were $21.4 million and general and administrative expenses were $3.3 million, both above the prior-year quarter, driving a quarterly net loss of $23.8 million, or $(8.75) per share.

Cash and cash equivalents were $95.4 million as of June 30, 2026, and the company subsequently completed an upsized initial public offering of 10,516,240 shares for $168.3 million in gross proceeds. BlossomHill believes this cash, together with IPO proceeds, will fund operations into the second quarter of 2028.

Operationally, BH-30643, the lead OMNI-EGFR™ inhibitor for EGFR-mutant NSCLC, received FDA Fast Track designation and is in a global Phase 1/2 trial. BH-30236, a CLK inhibitor for R/R AML and HR-MDS, holds orphan drug designation, and BH-501284, a preclinical pan-KRAS inhibitor, showed encouraging preclinical data, underscoring a broad, oncology-focused small-molecule pipeline.

BlossomHill Therapeutics, Inc. (BLSM) reported updated clinical data from its ongoing global Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer patients with secondary EGFR resistance mutations such as EGFR C797S. In patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, BH-30643 showed a 45% objective response rate (18/40) and an 88% disease control rate (35/40) as of the May 12, 2026 data cutoff, with efficacy follow-up through August 10, 2026. At efficacy follow-up, 63% of patients (25/40) remained on treatment, with a median follow-up of 6.9 months. The company states that BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events and notes that this presentation follows receipt of FDA Fast Track designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC. BlossomHill plans to advance BH-30643 into a Phase 2 trial in patients with C797S-positive NSCLC in 2027.

BlossomHill Therapeutics, Inc. (BLSM) is reported to have a significant shareholder group led by OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which together report beneficial ownership of 2,714,279 shares of common stock, representing 8.9% of outstanding shares.

These shares come from purchases of Series A and Series B preferred stock that converted 1-for-1 into common upon the IPO, plus 625,000 shares bought in the IPO at $16.00 per share. OrbiMed entities share voting and dispositive power over these shares through OrbiMed Private Investments VIII, LP, and OrbiMed executive Carl L. Gordon serves on BlossomHill’s board.

OPI VIII also holds registration rights (Form S-1, piggyback, and Form S-3) and is party to a 180‑day lock-up following the IPO, limiting sales and registration demands during that period. The filing states the position is held for investment purposes, with no current plan to change control or corporate structure.

BlossomHill Therapeutics, Inc. (BLSM) reports that Vivo Innovation Fund II Holdings, L.P., together with its general partner Vivo Innovation II, LLC, has filed a Schedule 13G disclosing beneficial ownership of the company’s common stock.

The filing states that Vivo Innovation Fund II Holdings, L.P. beneficially owns 1,681,240 shares of BlossomHill Therapeutics common stock, representing 5.5% of the outstanding class. The reporting persons have sole voting and sole dispositive power over these shares, with no shared voting or dispositive power. The ownership percentage is based on 30,643,660 shares outstanding after completion of BlossomHill Therapeutics’ initial public offering, as described in the company’s prospectus filed with the SEC on August 7, 2026.

BlossomHill Therapeutics, Inc. (BLSM) is the subject of a Schedule 13G reporting that Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. collectively report beneficial ownership of 1,808,533 shares of BlossomHill common stock. The filing states this represents 5.9% of the 30,643,660 shares of common stock outstanding, as referenced in BlossomHill’s prospectus filed on August 7, 2026. The Master Fund directly holds the 1,808,533 shares, while Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member of Perceptive Advisors, may be deemed to beneficially own these shares, all with shared voting and dispositive power.

BlossomHill Therapeutics, Inc. (BLSM) is the subject of a Schedule 13D filed by a group of Cormorant-managed investment funds and Bihua Chen, disclosing a significant ownership stake. The group reports beneficial ownership of 3,615,362 shares of common stock, representing 11.8% of BLSM’s outstanding shares based on 30,643,660 shares outstanding after the IPO.

The position consists largely of shares issued upon the automatic conversion of Series A and Series B Preferred Stock at BLSM’s August 10, 2026 initial public offering, plus 312,500 shares purchased in the IPO at $16.00 per share. The preferred investments totaled approximately $49.999 million, and the IPO purchase was $5 million, all funded from the reporting funds’ working capital. Bihua Chen, who is a director of BlossomHill and manager of the Cormorant entities, also holds stock options, including a grant for up to 23,904 shares at $16.00. The reporting persons describe the holdings as for investment purposes and indicate they may buy or sell shares and may engage with BLSM’s board and management on strategic and governance matters. They also hold registration rights, including demand, Form S-3, and piggyback rights, under a December 28, 2023 Investor Rights Agreement.

For BlossomHill Therapeutics, Inc. (BLSM), director Carl L. Gordon, through OrbiMed-related entities, reported automatic conversion of 1,039,996 shares of Series A Preferred Stock and 1,049,283 shares of Series B Preferred Stock into the same number of BlossomHill common shares upon the closing of the company’s initial public offering on August 10, 2026, without payment of consideration. In addition, OrbiMed Private Investments VIII, LP purchased 625,000 BlossomHill common shares in the IPO at $16.00 per share, reported as indirectly owned. The filing states that OrbiMed entities may be deemed to have voting and investment power over these securities, and that Carl L. Gordon, OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC each disclaim beneficial ownership except to the extent of any pecuniary interest.

BlossomHill Therapeutics, Inc. (BLSM) reported insider activity by OrbiMed-affiliated entities in connection with its initial public offering on August 10, 2026. OrbiMed Private Investments VIII, LP converted 1,039,996 shares of Series A Preferred Stock and 1,049,283 shares of Series B Preferred Stock into an equal number of common shares upon the IPO closing, without payment of consideration. In addition, it purchased 625,000 common shares at 16.0000 per share in the IPO. The reported OrbiMed entities may be deemed to share voting and investment power over these securities through their control relationships and each disclaims beneficial ownership beyond its pecuniary interest.

BlossomHill Therapeutics, Inc. (BLSM) reported that director Carl L. Gordon received a grant of 23,904 Director Stock Options on August 6, 2026. The options have an exercise price of $16.00 per share and expire on August 5, 2036. According to the vesting terms, 1/36 of the shares vest in equal monthly installments over three years following August 6, 2026. A footnote states that, under an agreement with OrbiMed Advisors LLC, Gordon is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC, which will ensure they are provided to OrbiMed Private Investments VIII, LP.